Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.

doi:10.1002/gcc.22427

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.

Genes, chromosomes & cancer - 1 Mar 2017

Leichsenring Jonas, Volckmar Anna-Lena, Magios Nikolaus, Morais de Oliveira Cristiano Manuel, Penzel Roland, Brandt Regine, Kirchner Martina, Bozorgmehr Farastuk, Thomas Michael, Schirmacher Peter, Warth Arne, Endris Volker, Stenzinger Albrecht

Abstract excerpt

Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the Epidermal Growth Factor Receptor (EGFR) benefit from targeted therapies. A synonymous polymorphism (rs1050171, p.Q787Q) was shown to be associated with improved overall survival (OS) in colorectal cancer patients. As data in NSCLC are limited, we retrospectively analyzed associations of p.Q787Q with clinicopathological...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Follow-Up Studies

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 27750395
DOI: 10.1002/gcc.22427

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma.PMID 27750395Read ↗

Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study.Semantic proximity Read ↗

A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.Semantic proximity Read ↗

The - 216G/T polymorphism in the EGFR gene: A review focusing on Non-Small lung cancer.Semantic proximity Read ↗

Synonymous Variants of Potential Significance Identified by a 52-Gene Clinical Sequencing Panel in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Germline EGFR c.2527G > A (p.V843I) variant and familial lung cancer.Semantic proximity Read ↗

Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma.Semantic proximity Read ↗

Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma.Semantic proximity Read ↗

EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.Semantic proximity Read ↗

Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.Semantic proximity Read ↗

Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.Semantic proximity Read ↗

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.Semantic proximity Read ↗

Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.